Arovella Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Arovella Therapeutics has a total shareholder equity of A$3.1M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$5.3M and A$2.2M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | n/a |
| Cash | AU$4.76m |
| Equity | AU$3.13m |
| Total liabilities | AU$2.19m |
| Total assets | AU$5.33m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: ALA's short term assets (A$5.2M) exceed its short term liabilities (A$2.2M).
Long Term Liabilities: ALA's short term assets (A$5.2M) exceed its long term liabilities (A$10.6K).
Debt to Equity History and Analysis
Debt Level: ALA is debt free.
Reducing Debt: ALA had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALA has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ALA is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.